Tissue Microarray Immunohistochemical Detection of Brachyury Is Not a Prognostic Indicator in Chordoma

PLoS ONE

Volumn 8, Issue 9, 2013, Pages

  Zhang, Linlin ^a,b   Guo, Shang ^a,c   Schwab, Joseph H ^a   Nielsen, G Petur ^a   Choy, Edwin ^a   Ye, Shunan ^a   Zhang, Zhan ^a,b   Mankin, Henry ^a   Hornicek, Francis J ^a   Duan, Zhenfeng ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b ZHENGZHOU UNIVERSITY   (China)

^c SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BRACHYURY; T BOX TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ADULT; AGE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CHORDOMA; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENDER; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; SACRUM; SPINE; TISSUE MICROARRAY; TUMOR LOCALIZATION;

AGE FACTORS; CHORDOMA; FEMALE; FETAL PROTEINS; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; PROGNOSIS; SEX FACTORS; T-BOX DOMAIN PROTEINS; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84884521720     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0075851     Document Type: Article

References (25)

1. Healey JH, Lane JM, (1989) Chordoma: a critical review of diagnosis and treatment. Orthop Clin North Am 20: 417-426. PubMed: 2662114.
2. Walcott BP, Nahed BV, Mohyeldin A, Coumans JV, Kahle KT, et al. (2012) Chordoma: current concepts, management, and future directions. Lancet Oncol 13: e69-e76. doi:10.1016/S1470-2045(11)70337-0. PubMed: 22300861.
3. Chugh R, Tawbi H, Lucas DR, Biermann JS, Schuetze SM, et al. (2007) Chordoma: the nonsarcoma primary bone tumor. Oncologist 12: 1344-1350. doi:10.1634/theoncologist.12-11-1344. PubMed: 18055855.
4. Vujovic S, Henderson S, Presneau N, Odell E, Jacques TS, et al. (2006) Brachyury, a crucial regulator of notochordal development, is a novel biomarker for chordomas. J Pathol 209: 157-165. doi:10.1002/path.1969. PubMed: 16538613.
5. Yang XR, Ng D, Alcorta DA, Liebsch NJ, Sheridan E, et al. (2009) T (brachyury) gene duplication confers major susceptibility to familial chordoma. Nat Genet 41: 1176-1178. doi:10.1038/ng.454. PubMed: 19801981.
6. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, et al. (2011) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223: 327-335. doi:10.1002/path.2816. PubMed: 21171078.
7. Shen J, Li CD, Yang HL, Lu J, Zou TM, et al. (2011) Classic chordoma coexisting with benign notochordal cell rest demonstrating different immunohistological expression patterns of brachyury and galectin-3. J Clin Neurosci 18: 96-99. doi:10.1016/j.jocn.2010.03.066. PubMed: 20855213.
8. Showell C, Binder O, Conlon FL, (2004) T-box genes in early embryogenesis. Dev Dyn 229: 201-218. doi:10.1002/dvdy.10480. PubMed: 14699590.
9. Arnold SJ, Stappert J, Bauer A, Kispert A, Herrmann BG, et al. (2000) Brachyury is a target gene of the Wnt/beta-catenin signaling pathway. Mech Dev 91: 249-258. doi:10.1016/S0925-4773(99)00309-3. PubMed: 10704849.
10. Satoh N, Tagawa K, Takahashi H, (2012) How was the notochord born? Evol Dev 14: 56-75. PubMed: 23016975.
11. Nelson AC, Pillay N, Henderson S, Presneau N, Tirabosco R, et al. (2012) An integrated functional genomics approach identifies the regulatory network directed by brachyury (T) in chordoma. J Pathol 228: 274-285. doi:10.1002/path.4082. PubMed: 22847733.
12. Le LP, Nielsen GP, Rosenberg AE, Thomas D, Batten JM, et al. (2011) Recurrent chromosomal copy number alterations in sporadic chordomas. PLOS ONE 6: e18846. doi:10.1371/journal.pone.0018846. PubMed: 21602918.
13. Presneau N, Shalaby A, Ye H, Pillay N, Halai D, et al. (2010) Role of the transcription factor T (brachyury) in the pathogenesis of sporadic chordoma: a genetic and functional-based study. J Pathol 223: 327-335. PubMed: 21171078.
14. Franco R, Caraglia M, Facchini G, Abbruzzese A, Botti G, (2011) The role of tissue microarray in the era of target-based agents. Expert Rev Anticancer Ther 11: 859-869. doi:10.1586/era.11.65. PubMed: 21707283.
15. Simon R, (2010) Applications of tissue microarray technology. Methods Mol Biol 664: 1-16. doi:10.1007/978-1-60761-806-5_1. PubMed: 20690047.
16. Pinder SE, Brown JP, Gillett C, Purdie CA, Speirs V, et al. (2013) The manufacture and assessment of tissue microarrays: suggestions and criteria for analysis, with breast cancer as an example. J Clin Pathol 66: 169-177. doi:10.1136/jclinpath-2012-201091. PubMed: 23087330.
17. Yang C, Hornicek FJ, Wood KB, Schwab JH, Choy E, et al. (2010) Characterization and analysis of human chordoma cell lines. Spine (Phila Pa 197635:: 1257-1264. PubMed: 20461036.
18. Roselli M, Fernando RI, Guadagni F, Spila A, Alessandroni J, et al. (2012) Brachyury, a driver of the epithelial-mesenchymal transition, is overexpressed in human lung tumors: an opportunity for novel interventions against lung cancer. Clin Cancer Res 18: 3868-3879. doi:10.1158/1078-0432.CCR-11-3211. PubMed: 22611028.
19. Palena C, Polev DE, Tsang KY, Fernando RI, Litzinger M, et al. (2007) The human T-box mesodermal transcription factor Brachyury is a candidate target for T-cell-mediated cancer immunotherapy. Clin Cancer Res 13: 2471-2478. doi:10.1158/1078-0432.CCR-06-2353. PubMed: 17438107.
20. Barresi V, Vitarelli E, Branca G, Antonelli M, Giangaspero F, et al. (2012) Expression of brachyury in hemangioblastoma: potential use in differential diagnosis. Am J Surg Pathol 36: 1052-1057. doi:10.1097/PAS.0b013e31824f4ce3. PubMed: 22446946.
21. Huang B, Cohen JR, Fernando RI, Hamilton DH, Litzinger MT, et al. (2013) The embryonic transcription factor Brachyury blocks cell cycle progression and mediates tumor resistance to conventional antitumor therapies. Cell Death. Drosophila Inf Serv 4: e682.
22. Hamilton DH, Litzinger MT, Fernando RI, Huang B, Palena C, (2012) Cancer vaccines targeting the epithelial-mesenchymal transition: tissue distribution of brachyury and other drivers of the mesenchymal-like phenotype of carcinomas. Semin Oncol 39: 358-366. doi:10.1053/j.seminoncol.2012.02.005. PubMed: 22595058.
23. Bydon M, Papadimitriou K, Witham T, Wolinsky JP, Bydon A, et al. (2012) Novel therapeutic targets in chordoma. Expert Opin Ther Targets.
24. Jambhekar NA, Rekhi B, Thorat K, Dikshit R, Agrawal M, et al. (2010) Revisiting chordoma with brachyury, a "new age" marker: analysis of a validation study on 51 cases. Arch Pathol Lab Med 134: 1181-1187. PubMed: 20670140.
25. Kilic N, Feldhaus S, Kilic E, Tennstedt P, Wicklein D, et al. (2011) Brachyury expression predicts poor prognosis at early stages of colorectal cancer. Eur J Cancer 47: 1080-1085. doi:10.1016/j.ejca.2010.11.015. PubMed: 21220197.